Trial · NCT01473589
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture | 12 months | Participants who were randomized and received at least 1 dose of study drug. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Radiographic Evidence of Healing | Randomization up to 12 months | Participants who were randomized and received at least 1 dose of study drug. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Pain Control During Ambulation | Up to 12 months | Participants who were randomized, received treatment, and had baseline and at least one nonmissing post-baseline measurement. Last observation carried forward (LOCF) values used. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Without Severe Fracture-Site Pain During 24 Hours Prior to Visit | Up to 12 months | Participants who were randomized, received at least 1 dose of study drug and had baseline and at least one nonmissing post-baseline measurement for severe fracture-site pain in the last 24 hours. LOCF values used. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Without Severe Fracture-Site Pain During Weight Bearing | Up to 12 months | Participants who were randomized, received at least 1 dose of study drug and had baseline and at least 1 nonmissing post-baseline measurement. LOCF values used. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Functional Evidence of Healing | 12 Months | Participants who were randomized, received at least 1 dose of study drug, and had either at least one nonmissing gait speed or non-ambulatory status. LOCF values used. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Able to Ambulate | Up to 12 months | Participants who were randomized and received at least 1 dose of study drug and had at least 1 nonmissing post-baseline measurement. LOCF values used. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Regain Their Prefracture Ambulatory Status | Up to 12 months | Participants who were randomized, received at least 1 dose of study drug, and had baseline and at least one nonmissing post-baseline measurement. LOCF values used. | percentage of participants | NUMBER |
| SECONDARY | Mean Change From Baseline to 6 Months in Worst Fracture-Site Pain | Baseline, 6 Months | Participants who were randomized and received at least 1 dose of study drug and had baseline and at least 1 nonmissing post-baseline measurement. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to 6 Months in Gait Speed | Baseline, up to 6 Months | Participants who were randomized, received at least 1 dose of study drug and had baseline and at least one nonmissing post-baseline measurement. | m/s | LEAST_SQUARES_MEAN |
| SECONDARY | Time to Revision Surgery | Baseline to revision surgery (up to 14.14 Months) | Participants who were randomized, received at least 1 dose of study drug, and who did not have revision surgery or if they had revision surgery, it was adjudicated as not being related to the initial hip fracture surgery. Participants censored: Teriparatide = 51; placebo = 51. | days | MEDIAN |
| SECONDARY | Mean Change From Baseline to 6 Months on Short Form-12 (SF-12) Physical (PCS) and Mental Component Summary (MCS) Scores | Baseline, up to 6 Months | Participants who were randomized, received at least 1 dose of study drug, were adjudicated as having the hip fracture in the neck of the femur and had baseline and at least 1 nonmissing post-baseline measurement. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to 6 Months on Western Ontario McMaster Osteoarthritis Index (WOMAC) | Baseline, up to 6 Months | Participants who were randomized, received at least 1 dose of study drug, were adjudicated as having the hip fracture in the neck of the femur and had baseline and at least 1 nonmissing post-baseline measurement. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Mean Change From Baseline to 6 Months on European Quality of Life Questionnaire (EQ-5D) Health State Score | Baseline, up to 6 Months | All randomized participants who were randomized, received at least 1 dose of study drug, were adjudicated as having the hip fracture in the neck of the femur, and had baseline and at least 1 nonmissing post-baseline measurement. | units on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01473589/outcomes